Stockscreener 앱 받기
0.87
0.00%
0.00
전일 마감가:
$0.87
열려 있는:
$0.88
하루 거래량:
4,986
Relative Volume:
0.08
시가총액:
$31.88M
수익:
$3.09M
순이익/손실:
$-7.36M
주가수익비율:
-3.8158
EPS:
-0.228
순현금흐름:
$-5.70M
1주 성능:
-2.54%
1개월 성능:
+14.47%
6개월 성능:
-15.53%
1년 성능:
-29.27%
1일 변동 폭
$0.87
$0.88
1주일 범위
$0.801
$0.9389
52주 변동 폭
$0.6546
$1.346
Dyadic International Inc De Stock (DYAI) Company Profile
명칭
Dyadic International Inc De
전화
561-743-8333
주소
1044 NORTH U.S. HIGHWAY ONE, JUPITER
Compare DYAI vs MOBBW, GOODO, PSNYW, SHMD, DWLD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 1.69 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
1.925 | 2.55B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
19.80 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.68 | 356.14M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
5.64 | 315.27M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
45.84 | 0 | 0 | 0 | 0 | 0.00 |
Dyadic International Inc De Stock (DYAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-23 | 재개 | H.C. Wainwright | Buy |
| 2025-09-08 | 개시 | Craig Hallum | Buy |
| 2022-07-18 | 다운그레이드 | Dawson James | Buy → Neutral |
| 2021-12-17 | 개시 | H.C. Wainwright | Buy |
Dyadic International Inc De 주식(DYAI)의 최신 뉴스
Dyadic International Stock: Biotechnology Innovator Focused on C1 Platform Amid Earnings Challenges - AD HOC NEWS
Dyadic International Earnings Call Highlights Commercial Pivot - TipRanks
Analysts Expect Breakeven For Dyadic International, Inc. (NASDAQ:DYAI) Before Long - Yahoo Finance
Dyadic International Q4 2025 Earnings Call Transcript - MarketBeat
Dyadic Applied BioSolutions: Innovative Microbial Protein Production Platforms for Life Sciences, Food, and Industrial Markets - Minichart
Dyadic International Inc (DYAI) Q4 2025 Earnings Call Highlights: Navigating Transition with ... By GuruFocus - ca.investing.com
Dyadic International’s ability to sustain operations for the next year and avoid significant dilution depends on the effectiveness of its shift toward commercial strategies - Bitget
Dyadic (DYAI) Q4 2025 Earnings Call Transcript - theglobeandmail.com
Earnings call transcript: Dyadic Q4 2025 reveals revenue decline, stock up 3.32% - Investing.com Australia
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress - Yahoo Finance Singapore
Dyadic (NASDAQ: DYAI) posts lower 2025 revenue and wider annual net loss - Stock Titan
EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity - AOL.com
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices - GlobeNewswire
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026 - The Manila Times
Dyadic to detail full-year 2025 results in March 25 investor call - Stock Titan
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th - GlobeNewswire
Decliners Report: Can Dyadic International Inc outperform under higher oil pricesWeekly Market Outlook & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Dyadic International Establishes At-the-Market Equity Offering Program - The Globe and Mail
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free) - Yahoo Finance
Dyadic Applied BioSolutions and Inzymes ApS Announce - GlobeNewswire
Alpha-Amylase Market Forecast Points Higher Toward 2035 Amid Sustainable Industrial ShiftNews and Statistics - IndexBox
Dyadic's Strategic Pivot: From Platform to Product - AD HOC NEWS
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin - Yahoo Finance
Segmentation, Major Trends, and Competitive Overview of the Industrial Biocatalysts Market - openPR.com
Enzyme Engineering Market to Get an Explosive Growth | Novozymes - openPR.com
Dyadic International (NASDAQ:DYAI) Stock Passes Below Fifty Day Moving Average – Should You Sell? - Defense World
Dyadic International (NASDAQ:DYAI) Share Price Crosses Below 50 Day Moving Average – Should You Sell? - Defense World
Dyadic International’s Tiny Stock, Big Volatility: Can DYAI’s Latest Rally Really Last? - AD HOC NEWS
Enzyme Engineering Market Set for Rapid Growth and Trend - openPR.com
Dyadic International Inc. (NASDAQ:DYAI) Short Interest Up 25.7% in December - Defense World
iAccess Alpha’s Virtual Best Ideas Winter Investment Conference December 9-10, 2025 - Ventura County Star
Dyadic International Amends Convertible Notes, Extends Maturity Timeline - TipRanks
Dyadic International receives Nasdaq notice for minimum bid price deficiency - Investing.com
Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets - GlobeNewswire
Analysis of Market Segmentation, Major Trends, and Competitive Dynamics in the Cellulase Market - openPR.com
Dyadic Applied BioSolutions Establishes Commercial - GlobeNewswire
Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins - Yahoo Finance
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 - Finviz
Earnings call transcript: Dyadic’s Q3 2025 results miss forecasts, stock dips - Investing.com
Earnings call transcript: Dyadic's Q3 2025 results miss forecasts, stock dips - Investing.com UK
Industrial Enzymes Market worth $12.01 billion by 2030 - MarketsandMarkets
Dyadic International Inc De (DYAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.76%
0.79%
자본화:
|
볼륨(24시간):